The Effectiveness of the Android Application as a Pharmaceutical Education Tool in Hypertensive Patients

Sponsor
Universitas Padjadjaran (Other)
Overall Status
Recruiting
CT.gov ID
NCT05728723
Collaborator
(none)
100
1
2
3
33.1

Study Details

Study Description

Brief Summary

Hypertension is a worldwide public health challenge due to its high prevalence and along with an increased risk of complications of other diseases that are more dangerous if not managed properly. An estimated 1.4 billion people worldwide have high blood pressure, but only 14% can control it. Knowledge in patients with hypertension can prevent complications through hypertension treatment. Increasing knowledge can be done by providing education in the form of counseling by pharmacists to hypertensive patients. Counseling activities carried out by pharmacists can be supported by a technological approach. One of the uses in smartphone technology is by creating an android-based mobile application that can be developed to support pharmaceutical care. Education conducted by pharmacists can increase knowledge that will affect hypertension treatment adherence, and this education can also improve blood pressure control so that it can improve the quality of life. The purpose of this study is to analyze the influence of pharmaceutical education and android applications as counseling aids on knowledge of hypertensive patients, adherence of hypertensive patients, therapeutic outcomes of hypertensive patients, and quality of life related to the health of hypertensive patients compared to providing regular education by pharmacists to hypertensive patients at the Primary Health Care. The method used in this study is a Randomized Controlled Trial with Pre test - Posttest Control Group Design. Randomization was carried out to determine one Primary Health Care to be used as the intervention group and one Primary Health Care to be used as the control group. Samples were obtained by purposive sampling method at the selected Primary Health Care as the intervention group and the selected Primary Health Care as the control group. Pharmacist provides education to intervention groups with android applications as counseling aids and in control groups only standard counseling is provided. Pre-test data collection by taking primary and secondary data of patients at the first meeting and post-test data collection were taken prospectively through face-to-face interviews and questionnaires on hypertensive patients participants for three months by observing the influence of android applications as counseling aids on knowledge of hypertensive diseases, adherence to antihypertensive treatment, outcome therapy and quality of life.

Condition or Disease Intervention/Treatment Phase
  • Device: Android Application
  • Behavioral: Pharmacy education
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Care Provider)
Primary Purpose:
Prevention
Official Title:
The Influence of Pharmacist Education and Android Application on Knowledge, Adherence, Clinical Outcome and Quality of Life of Hypertension Prolanis Patients in Public Health Centers in Bandar Lampung City
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Jun 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention group

Pharmacy Education with Android Application as a Tool Conducted for Three Months in Hypertensive Patients to Improve Knowledge, Adherence, Outcome Therapy and Quality of Life

Device: Android Application
Android Application for 3 months

Behavioral: Pharmacy education
Pharmacy education in hypertensive patients

Active Comparator: Pharmacy education

Pharmacy education in hypertensive patients

Behavioral: Pharmacy education
Pharmacy education in hypertensive patients

Outcome Measures

Primary Outcome Measures

  1. Knowledge of hypertensive diseases [90 days]

    Measurement by Hypertension Knowledge-Level Scale (HK-LS) questionary.

  2. Adherence to antihypertensive treatment [90 days]

    Measurement by Medication Adherence Report Scale (MARS) questionary.

Secondary Outcome Measures

  1. Blood pressure [90 days]

    Measurement by blood pressure measuring device.

  2. Quality of life related to the health [90 days]

    Measurement by Short Form-36 (SF-36) questionary.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients aged ≥ 18 years, male and female who are willing to be respondents.

  • Patients diagnosed with hypertension or currently taking ≥ 1 antihypertensive drug.

  • Hypertension patients who carry out routine control and receive anti-hypertensive drugs for at least 3 months at the Health Center.

  • Not illiterate and owns a smartphone.

  • Patients who are willing to participate in the study by signing an informed consent.

Exclusion Criteria:
  • Hypertensive patients with comorbidities, such as diabetes mellitus, heart failure, liver disorders, kidney disorders, psychiatric disorders, and cancer.

  • Physical and mental disabilities such as deaf, blind, and psychiatric disorders.

  • The patient is pregnant

  • Currently taking hormonal drugs and other routine drugs such as TB, HIV and AIDS drugs.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Health Centers Bandar Lampung Lampung Indonesia

Sponsors and Collaborators

  • Universitas Padjadjaran

Investigators

  • Principal Investigator: Abdul K Tasib, S.Si., Apt., Faculty of Pharmacy Universitas Padjadjaran Bandung

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Universitas Padjadjaran
ClinicalTrials.gov Identifier:
NCT05728723
Other Study ID Numbers:
  • Pharm-202301.01
First Posted:
Feb 15, 2023
Last Update Posted:
Feb 15, 2023
Last Verified:
Feb 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 15, 2023